Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21965663
Jung MS, et al. (2011) Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. J Biol Chem 286, 40401-12 21965663
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S163-p - RCAN1 (human)
Modsite: PDKQFLIsPPAsPPV SwissProt Entrez-Gene
Orthologous residues
RCAN1 (human): S163‑p, RCAN1 iso2 (human): S108‑p, RCAN1 iso3 (human): S82‑p, RCAN1 (mouse): S161‑p, RCAN1 (rat): S108‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, Down syndrome
Relevant cell lines - cell types - tissues:  'brain, hippocampus' [DYRK1A (human), transgenic], HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Comments:  phosphorylation at S167 by DYRK1A primes for S163 phosphorylation by GSK3B

S167-p - RCAN1 (human)
Modsite: FLIsPPAsPPVGWKQ SwissProt Entrez-Gene
Orthologous residues
RCAN1 (human): S167‑p, RCAN1 iso2 (human): S112‑p, RCAN1 iso3 (human): S86‑p, RCAN1 (mouse): S165‑p, RCAN1 (rat): S112‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, Down syndrome
Relevant cell lines - cell types - tissues:  'brain, hippocampus' [DYRK1A (human), transgenic], HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE DYRK1A (human)

T179-p - RCAN1 (human)
Modsite: WKQVEDAtPVINYDL SwissProt Entrez-Gene
Orthologous residues
RCAN1 (human): T179‑p, RCAN1 iso2 (human): T124‑p, RCAN1 iso3 (human): T98‑p, RCAN1 (mouse): T177‑p, RCAN1 (rat): T124‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, Down syndrome
Relevant cell lines - cell types - tissues:  'brain, hippocampus' [DYRK1A (human), transgenic], HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

T208-p - RCAN1 (human)
Modsite: LHAATDTtPSVVVHV SwissProt Entrez-Gene
Orthologous residues
RCAN1 (human): T208‑p, RCAN1 iso2 (human): T153‑p, RCAN1 iso3 (human): T127‑p, RCAN1 (mouse): T206‑p, RCAN1 (rat): T153‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, Down syndrome
Relevant cell lines - cell types - tissues:  'brain, hippocampus' [DYRK1A (human), transgenic], HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

T247-p - RCAN1 (human)
Modsite: QtRRPEYtPIHLS__ SwissProt Entrez-Gene
Orthologous residues
RCAN1 (human): T247‑p, RCAN1 iso2 (human): T192‑p, RCAN1 iso3 (human): T166‑p, RCAN1 (mouse): T246‑p, RCAN1 (rat): T194‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  Alzheimer's disease, Down syndrome
Relevant cell lines - cell types - tissues:  'brain, hippocampus' [DYRK1A (human), transgenic], HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE DYRK1A (human)
Downstream Regulation
Effect of modification (function):  protein stabilization
Effect of modification (process):  transcription, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PPP3CA (human) Disrupts activity, inhibited co-immunoprecipitation
Comments:  inhibits calcineurin phosphatase activity and NFAT-dependent transcription